Sydney Jennings

Sydney Jennings is a healthcare writer with extensive experience covering medical topics. She has published numerous articles on various health conditions and treatments, providing valuable information to readers seeking to understand and manage their health concerns. Her work focuses on translating complex medical research into easily digestible content for the general public. Through her writing, Sydney aims to empower individuals with the knowledge they need to make informed decisions about their health and well-being.

Biography:  https://www.patientcareonline.com/authors/sydney-jennings

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

85%

Examples:

  • Final cohort numbered 18,366 participants matched by propensity score (9193 using tirzepatide, 9192 using semaglutide).
  • Mounjaro widened its lead through six and 12 months of treatment, leading to 4.3% and 6.9% greater weight loss than Ozempic, respectively.
  • On-treatment changes in weight for tirzepatide-treated group were larger at 3, 6, and 12 months of follow-up compared to semaglutide.
  • Participants had baseline weight measurement within 60 days of first GLP-1RA dispense, no prior exposure to GLP-1 RA medications.
  • Patients on Mounjaro were more likely to lose weight and achieved greater weight loss than those on Ozempic.
  • Tirzepatide group was significantly more likely to reach weight loss of greater than 5%, greater than 10%, and greater than 15% compared to semaglutide group.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

Mounjaro Outperforms Ozempic in Weight Loss: Study Finds 7% Greater Average Loss After One Year

Mounjaro Outperforms Ozempic in Weight Loss: Study Finds 7% Greater Average Loss After One Year

Broke On: Tuesday, 09 July 2024 In a JAMA Internal Medicine study, researchers compared outcomes of over 18,000 US patients on Eli Lilly's Mounjaro (tirzepatide) and Novo Nordisk's Ozempic (semaglutide), finding that Mounjaro led to greater weight loss with 81.8% vs. 66.5% achieving five percent or more weight loss, and an average seven percent greater weight loss at twelve months.